DK1246623T3 - Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf - Google Patents

Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf

Info

Publication number: DK1246623T3
Authority: DK; Denmark
Prior art keywords: adenosine; compounds; receptor; compounds specific; subject
Prior art date: 1999-12-02

Application number

DK00988011T

Other languages

English (en)

Inventor

Arlindo L Castelhano

David J Witter

Bryan Mckibben

Original Assignee

Osi Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-02

Filing date

2000-12-01

Publication date

2006-11-13

1999-12-02 Priority claimed from US09/454,075 external-priority patent/US6686366B1/en

1999-12-02 Priority claimed from US09/454,074 external-priority patent/US6878716B1/en

2000-12-01 Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc

2006-11-13 Application granted granted Critical

2006-11-13 Publication of DK1246623T3 publication Critical patent/DK1246623T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Immunology (AREA)
Obesity (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

DK00988011T 1999-12-02 2000-12-01 Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf DK1246623T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US45425499A	1999-12-02	1999-12-02
US09/454,075 US6686366B1 (en)	1998-06-02	1999-12-02	Compounds specific to adenosine A3 receptor and uses thereof
US09/454,074 US6878716B1 (en)	1998-06-02	1999-12-02	Compounds specific to adenosine A1 receptor and uses thereof

Publications (1)

Publication Number	Publication Date
DK1246623T3 true DK1246623T3 (da)	2006-11-13

Family

ID=27412585

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00988011T DK1246623T3 (da)	1999-12-02	2000-12-01	Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf

Country Status (15)

Country	Link
EP (2)	EP1246623B1 (da)
JP (1)	JP2003519102A (da)
KR (1)	KR100840727B1 (da)
AT (1)	ATE335489T1 (da)
AU (1)	AU784878B2 (da)
CA (1)	CA2393179A1 (da)
CY (1)	CY1107653T1 (da)
DE (1)	DE60030002T2 (da)
DK (1)	DK1246623T3 (da)
ES (1)	ES2269217T3 (da)
HK (1)	HK1050319B (da)
IL (2)	IL149935A0 (da)
MX (1)	MXPA02005357A (da)
PT (1)	PT1246623E (da)
WO (1)	WO2001039777A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100528874C (zh)	1998-06-02	2009-08-19	Osi药物公司	吡咯并[2,3d]嘧啶组合物及其应用
US6660731B2 (en)	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
JP4170752B2 (ja)	2000-09-15	2008-10-22	バーテックスファーマシューティカルズインコーポレイテッド	プロテインキナーゼインヒビターとして有用なピラゾール化合物
US7473691B2 (en)	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
UA74228C2 (uk) *	2000-12-01	2005-11-15	Осі Фармасьютікалз, Інк.	ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ, СПЕЦИФІЧНІ ДО АДЕНОЗИНОВОГО A<sub>1</sub>, A<sub>2А</sub> І A<sub>3</sub> РЕЦЕПТОРА, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
YU42703A (sh) *	2000-12-01	2006-03-03	Osi Pharmaceuticals Inc.	Jedinjenja specifična za dobijanje adenozinske a1,a2a i a3 receptore i njihove primene
ATE340172T1 (de)	2000-12-21	2006-10-15	Vertex Pharma	Pyrazolverbindungen als protein- kinasehemmer
UA80258C2 (en) *	2001-09-06	2007-09-10	Biogen Inc	Methods of treating pulmonary disease
DE10148883A1 (de)	2001-10-04	2003-04-10	Merck Patent Gmbh	Pyrimidinderivate
US7504407B2 (en)	2001-11-30	2009-03-17	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 and A3 receptors and uses thereof
ES2528384T3 (es)	2001-12-12	2015-02-09	The Government Of The United States Of America, As Represented By The Secretary Department Of Healt	Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
CN1620294A (zh)	2001-12-20	2005-05-25	Osi药物公司	嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
DK1467995T3 (da) *	2001-12-20	2010-09-20	Osi Pharm Inc	Pyrrolopyrimidin-A2b-selektive antagonistforbindelser, deres syntese og anvendelse
US20030229067A1 (en)	2001-12-20	2003-12-11	Arlindo Castelhano	Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
BR0308451A (pt)	2002-03-13	2005-01-11	Euro Celtique Sa	Composto, composição farmacêutica, métodos para o tratamento, prevenção ou melhoria de disfunção e método de fabricação de composto
MY141867A (en)	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
NZ550883A (en)	2002-08-02	2008-06-30	Vertex Pharma	Pyrazole compositions useful as inhibitors of glycogen synthase kinase-3 (GSK-3)
AU2004230928B2 (en) *	2003-04-09	2010-12-02	Exelixis, Inc.	Tie-2 modulators and methods of use
AR043880A1 (es) *	2003-04-22	2005-08-17	Solvay Pharm Gmbh	Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2005004875A1 (ja) *	2003-07-14	2005-01-20	Sankyo Company, Limited	経肺投与用医薬組成物
ES2435081T3 (es)	2005-11-03	2013-12-18	Vertex Pharmaceuticals Incorporated	Aminopirimidinas útiles como inhibidores de las cinasas
CN101443344B (zh)	2006-03-27	2012-08-29	大塚化学株式会社	海藻糖化合物及含有该化合物的药物
EP2007373A4 (en) *	2006-03-29	2012-12-19	Foldrx Pharmaceuticals Inc	INHIBITION OF ALPHA SYNUCLEINE TOXICITY
TW200808819A (en) *	2006-06-19	2008-02-16	Solvay Pharm Gmbh	Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
ATE535243T1 (de) *	2007-05-11	2011-12-15	Santen Pharmaceutical Co Ltd	Prophylaktisches oder therapeutisches mittel für posteriore augenerkrankung mit selektivem nicht- ergot-d2-rezeptoragonist als wirkstoff
WO2009052376A1 (en)	2007-10-18	2009-04-23	Musc Foundation For Research Development	Methods for the diagnosis of genitourinary cancer
AR070127A1 (es)	2008-01-11	2010-03-17	Novartis Ag	Pirrolo - pirimidinas y pirrolo -piridinas
ES2617339T3 (es) *	2010-12-16	2017-06-16	Calchan Limited	Derivados de pirrolopirimidina inhibidores de ASK1
MX2014014832A (es) *	2012-06-07	2015-02-12	Hoffmann La Roche	Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
GB201711234D0 (en)	2017-07-12	2017-08-23	Galapagos Nv	Pyrrolopyrimidine and pyrrolopyridine derivatives
KR20240018000A (ko) *	2022-08-01	2024-02-13	주식회사 넥스트젠바이오사이언스	A3 아데노신 수용체 작용제로서의 신규한 퓨린 유도체 화합물
WO2024233605A1 (en) *	2023-05-08	2024-11-14	Tango Therapeutics, Inc.	Compounds and their use against cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3910913A (en) *	1969-11-04	1975-10-07	American Home Prod	4,5-Diamino-7H-pyrrolo{8 2,3-d{9 pyrimidine derivatives
US5516894A (en)	1992-03-11	1996-05-14	The General Hospital Corporation	A2b -adenosine receptors
EP0633886B1 (en) *	1992-04-03	2000-10-18	PHARMACIA & UPJOHN COMPANY	Pharmaceutically active bicyclic-heterocyclic amines
WO1995011681A1 (en)	1993-10-29	1995-05-04	Merck & Co., Inc.	Human adenosine receptor antagonists
IT1277392B1 (it)	1995-07-28	1997-11-10	Schering Plough S P A	Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
US5780450A (en)	1995-11-21	1998-07-14	Alcon Laboratories, Inc.	Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
WO1997033879A1 (en)	1996-03-15	1997-09-18	Merck & Co., Inc.	Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
JPH09291089A (ja)	1996-04-26	1997-11-11	Yamanouchi Pharmaceut Co Ltd	新規な５−チアゾリルウラシル誘導体又はその塩
US5786360A (en)	1996-11-19	1998-07-28	Link Technology Incorporated	A1 adenosine receptor antagonists
JP2003517423A (ja)	1997-07-29	2003-05-27	メドコリサーチ、インコーポレイテッド	アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド
CN100528874C (zh) *	1998-06-02	2009-08-19	Osi药物公司	吡咯并[2,3d]嘧啶组合物及其应用
US9816053B2 (en)	2015-03-26	2017-11-14	Melynda S DelCotto	Candle having a wooden wick with figured grain

2000
- 2000-12-01 EP EP00988011A patent/EP1246623B1/en not_active Expired - Lifetime
- 2000-12-01 ES ES00988011T patent/ES2269217T3/es not_active Expired - Lifetime
- 2000-12-01 DE DE60030002T patent/DE60030002T2/de not_active Expired - Lifetime
- 2000-12-01 MX MXPA02005357A patent/MXPA02005357A/es active IP Right Grant
- 2000-12-01 IL IL14993500A patent/IL149935A0/xx unknown
- 2000-12-01 AT AT00988011T patent/ATE335489T1/de active
- 2000-12-01 DK DK00988011T patent/DK1246623T3/da active
- 2000-12-01 KR KR1020027007039A patent/KR100840727B1/ko not_active IP Right Cessation
- 2000-12-01 CA CA002393179A patent/CA2393179A1/en not_active Abandoned
- 2000-12-01 WO PCT/US2000/032702 patent/WO2001039777A1/en active Application Filing
- 2000-12-01 EP EP06016543A patent/EP1731520A1/en not_active Withdrawn
- 2000-12-01 PT PT00988011T patent/PT1246623E/pt unknown
- 2000-12-01 AU AU24270/01A patent/AU784878B2/en not_active Ceased
- 2000-12-01 JP JP2001541509A patent/JP2003519102A/ja active Pending
2003
- 2003-03-28 HK HK03102257.1A patent/HK1050319B/zh not_active IP Right Cessation
2006
- 2006-09-04 CY CY20061101246T patent/CY1107653T1/el unknown
2009
- 2009-07-15 IL IL199869A patent/IL199869A0/en unknown

Also Published As

Publication number	Publication date
HK1050319B (zh)	2007-04-04
DE60030002D1 (de)	2006-09-21
ATE335489T1 (de)	2006-09-15
ES2269217T3 (es)	2007-04-01
KR20020064327A (ko)	2002-08-07
CA2393179A1 (en)	2001-06-07
AU2427001A (en)	2001-06-12
IL199869A0 (en)	2011-08-01
MXPA02005357A (es)	2003-05-19
KR100840727B1 (ko)	2008-06-23
EP1246623A1 (en)	2002-10-09
EP1246623A4 (en)	2003-05-14
WO2001039777A8 (en)	2001-11-08
EP1731520A1 (en)	2006-12-13
EP1246623B1 (en)	2006-08-09
CY1107653T1 (el)	2013-04-18
DE60030002T2 (de)	2007-03-08
PT1246623E (pt)	2006-12-29
AU784878B2 (en)	2006-07-13
JP2003519102A (ja)	2003-06-17
HK1050319A1 (en)	2003-06-20
IL149935A0 (en)	2002-11-10
WO2001039777A1 (en)	2001-06-07

Publication	Publication Date	Title
DK1246623T3 (da)	2006-11-13	Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf
AP1893A (en)	2008-09-23	Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof
DK1450811T3 (da)	2010-02-15	Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
NZ522326A (en)	2006-03-31	Adenosine A2A receptor antagonists
CY1113610T1 (el)	2016-06-22	Συνθεσεις και μεθοδοι για αγωγη μιτοχονδριακων παθησεων
BR0317436A (pt)	2005-11-16	Usos de antagonistas do receptor a2a de adenosina
DK1695983T3 (da)	2009-05-18	Glucagon-lignende peptid-1 analoger
BR0011854A (pt)	2002-06-11	Agonistas de receptores de a2a de c-pirazola
AP2003002911A0 (en)	2003-12-31	An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
ZA909141B (en)	1991-08-28	Therapeutically active chloro substituted benzimidazoles,processes for their preparation as well as their use
BRPI0011856B8 (pt)	2021-05-25	agonistas de receptor a2a de n-pirazol
PT819002E (pt)	2003-01-31	Utilizacao de derivados de imidazol¬1,2-a\|piridina-3-acetamida para o tratamento terapeutico de sindromas neuro-psiquiatricos associados com a disfuncao dos circuitos neurais dos ganglios basais
MXPA03009185A (es)	2004-02-17	Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
BR0116481A (pt)	2004-01-06	Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6
EE04905B1 (et)	2007-10-15	Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks
HK1061817A1 (en)	2004-10-08	Use of flumazenil to produce a medicament for the treatment of cocaine dependency
ES2191908T3 (es)	2003-09-16	4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
ES1022449Y (es)	1993-10-01	Aparato terapeutica para tratamiento de sintomas ocasionados por enfermedades.
BR0313665A (pt)	2005-06-14	Utilização de bupropion para o tratamento da sìndrome das pernas inquietas
ES2171838T3 (es)	2002-09-16	Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para el tratamiento del trastorno bipolar.
BR9912008A (pt)	2001-04-10	Método de tratamento
BR0307479A (pt)	2004-12-07	Compostos orgânicos
IT1274012B (it)	1997-07-14	N-acetiltriptamine-2-sostituite, antagoniste ad elevata affinita' del recettore della melatonina
KR930004444U (ko)	1993-03-20	피로회복을 위한 다목적 신체안마기
AU2002338309A1 (en)	2002-10-21	Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease